Work Here?
About Bluesight
Industries
AI & Machine Learning
Healthcare
Company Size
51-200
Company Stage
Debt Financing
Total Funding
$36.5M
Headquarters
Washington, District of Columbia
Founded
2011
Overview
Bluesight focuses on improving supply chain processes in the healthcare sector, specifically for hospital pharmacies. The company uses AI and machine learning to analyze data related to the medication lifecycle, providing actionable insights that help hospitals manage their medications more effectively. Their Medication Intelligence™ solutions enhance visibility and predictability in medication management, allowing pharmacies to operate more efficiently, lower medication costs, and ensure compliance and safety. Unlike many competitors, Bluesight specifically targets the needs of hospital pharmacies and has established a strong presence, serving over 1,600 hospitals in the U.S. and Canada. The goal of Bluesight is to optimize pharmacy practices and improve overall healthcare delivery through better medication management.
Simplify's Take
What believers are saying
- AI-driven predictive analytics can enhance operational efficiency and reduce medication waste.
- The rise of digital twins enables accurate simulations in medication management processes.
- Expansion of 5G networks facilitates real-time medication management analytics.
What critics are saying
- Increased competition from Kit Check's RFID technology threatens Bluesight's market share.
- Rebranding to ControlCheck may cause temporary confusion among existing clients.
- Thoma Bravo's investment may pressure Bluesight for rapid expansion, straining resources.
What makes Bluesight unique
- Bluesight leverages AI and machine learning for actionable analytics in medication management.
- The company serves over 1,600 hospitals in the U.S. and Canada.
- Bluesight's Medication Intelligence solutions enhance visibility and predictability in medication management.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$36.5M
Below
Industry Average
Funded Over
5 Rounds
Kleiner PerkinsBenefits
Health, Dental, and Vision Insurance
Maternity & Paternity Leave
Domestic Partner Benefits
401(k) with Company Match
Health Savings Account
Home Office Stipend
Health & Dependent Care FSA Insurance
Employee Assistance Program
Unlimited Paid Time Off
Mental Health Stipend
Growth & Insights and Company News
6 month growth
↓ -7%1 year growth
↓ -7%2 year growth
↓ -6%In August 2022, Kit Check, the leading automation vendor in medication intelligence, announced that its proprietary Radio Frequency Identification (RFID) technology incorporated in the new KinetiX Propofol syringes being developed by Genixus, a pharmaceutical company and U.S. FDA-registered repackager and 503B outsourcing provider focused on transforming acute and critical care medicines.
In August 2022, Kit Check, the leading automation vendor in medication intelligence, announced that its proprietary Radio Frequency Identification (RFID) technology incorporated in the new KinetiX Propofol syringes being developed by Genixus, a pharmaceutical company and U.S. FDA-registered repackager and 503B outsourcing provider focused on transforming acute and critical care medicines.
/PRNewswire/ -- Thoma Bravo, a leading software investment firm, today announced the closing of a strategic growth investment in Bluesight, the Medication...
It’s with great pleasure that KitCheck, Inc. announce Bluesight for Controlled Substances’ rebrand to ControlCheck.
SAN RAMON, Calif.--(BUSINESS WIRE)--Today, the first membership-driven industry alliance advancing radio-frequency identification (RFID) technology in pharmaceuticals announced its rebrand to UnitVisID Alliance, as the new name for the DoseID Consortium. The name change reflects the organization’s commitment and mission to ensure the quality, performance, and interoperability of RFID-tagged pharmaceutical products as they move through the supply chain – from manufacturing to patient use. The confluence of the COVID-19 pandemic, drug shortages, and staff shortages have accelerated RFID technology adoption. Emergen Research forecasts that the market for RFID in healthcare will reach almost US $15 billion in 2028 globally from $4.24 billion in 2020
There are no jobs for Bluesight right now.
Find jobs on Simplify and start your career today
About Bluesight
Industries
AI & Machine Learning
Healthcare
Company Size
51-200
Company Stage
Debt Financing
Total Funding
$36.5M
Headquarters
Washington, District of Columbia
Founded
2011
There are no jobs for Bluesight right now.
Find jobs on Simplify and start your career today